Legend Biotech (LEGN) Receivables - Other (2019 - 2025)
Legend Biotech's (LEGN) quarterly Receivables - Other came in at $1.2 million in Q3 2025, down 38.71% YoY from $1.9 million in Q3 2024, and up 11.14% on a QoQ basis from $1.0 million in Q2 2025.
Legend Biotech (LEGN) Receivables - Other (2019 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Receivables - Other data on file, last reported at $1.2 million in Q3 2025.
- Quarterly Receivables - Other fell 38.71% year-over-year to $1.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.2 million (down 38.71% YoY) and the FY2024 annual result came in at $780000.0, down 1.27% from the prior year.
- Receivables - Other grew to $1.2 million in Q3 2025, from $1.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $50.0 million in Q4 2021 to a low of $46000.0 in Q2 2021.
- A 5-year average of $12.0 million and a median of $1.1 million in 2024 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other sank 98.1% — and 2024, when it decreased 1.27%.
- Tracing LEGN's Receivables - Other over 5 years: stood at $50.0 million in 2021, then slumped by 98.1% to $948000.0 in 2022, then fell by 16.67% to $790000.0 in 2023, then retreated by 1.27% to $780000.0 in 2024, then soared by 49.62% to $1.2 million in 2025.
- The last three Receivables - Other figures came in at $1.2 million (Q3 2025), $1.0 million (Q2 2025), and $954000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 954,000.00 |
| Mar 31, 2025 | 954,000.00 |
| Dec 31, 2024 | 780,000.00 |
| Dec 31, 2024 | 780,000.00 |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 790,000.00 |
| Dec 31, 2023 | 790,000.00 |
| Sep 30, 2023 | 48.33 Mn |
| Sep 30, 2023 | 48.33 Mn |
| Jun 30, 2023 | 46.69 Mn |
| Jun 30, 2023 | 46.69 Mn |